Literature DB >> 8977761

Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.

M Sampson1, C Kong, A Patel, R Unwin, H S Jacobs.   

Abstract

OBJECTIVE: Hyperinsulinaemic women with the polycystic ovary syndrome (PCOS) may be at increased risk of vascular disease later in life, mediated by blood pressure or lipid abnormalities or by elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) activity. PAI-1 may also be involved in ovarian follicle development and ovarian connective tissue remodelling. We measured plasma PAI-1 activity and 24-hour ambulatory blood pressure records in women with and without PCOS.
DESIGN: Cross-sectional study of three groups. PATIENTS: Twenty-four non-obese women with a classic ovarian ultrasound appearance of PCO and extreme menstrual disturbance (Group 1), 26 matched controls with a normal menstrual cycle and an ultrasound appearance of PCO (Group 2) and 10 matched controls with a normal menstrual cycle and normal ovarian ultrasound (Group 3). MEASUREMENTS: Twenty-four hour ambulatory blood pressure recordings (Spacelabs 90207), ovarian ultrasonography, fasting plasma insulin and glucose, plasma PAI-1 activity, HDL and total cholesterol, triglycerides, gonadotrophins and testosterone. Family history of premature vascular disease.
RESULTS: Median fasting plasma insulin was significantly higher in Group 1 (45.8 pmol/l, range 12.9-161.9) than in Group 2 (28.1 pmol/l; range 13.6-91; P < 0.05) or Group 3 (26.0 pmol/l; range 13.5-63.3; P < 0.05). There were no differences between groups in 24-hour, daytime or night-time ambulatory blood pressure measurements, and no relation between plasma insulin and any blood pressure variable. Mean plasma PAI-1 activity was higher in Group 1 (10.0 +/- 7.1 AU/l) than in Group 2 (6.0 +/- 4.6 AU/l; P < 0.05) or Group 3 (5.1 +/- 3.5 AU/l; P = 0.06). There was a significant independent direct relation between fasting plasma insulin and PAI-activity (r = 0.41, R2 = 0.154; F1,59 = 11.38; P = 0.001). Groups did not differ in parental history of premature vascular disease, or in mean HDL or fasting triglyceride levels.
CONCLUSIONS: The only measurable vascular risk factor associated with hyperinsulinaemia and menstrual disturbance in non-obese women with PCOS is an elevated plasma PAI-1 activity. These women did not differ from controls in ambulatory blood pressure profiles, lipid measurements or in a parental history of premature vascular disease. PAI-1 and plasminogen are involved in ovarian follicle maturation and the present finding suggests a biologically plausible link between hyperinsulinaemia, anovulation and vascular risk in PCOS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977761     DOI: 10.1046/j.1365-2265.1996.00863.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  24 in total

Review 1.  Insulin resistance and polycystic ovary syndrome.

Authors:  David A Ehrmann
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

Review 2.  Neuroendocrine dysfunction in PCOS: a critique of recent reviews.

Authors:  Suhail A R Doi
Journal:  Clin Med Res       Date:  2008-09

3.  Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome.

Authors:  S A R Doi; M Al-Zaid; P A Towers; C J Scott; K A S Al-Shoumer
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

4.  Ovarian hypertension: polycystic ovary syndrome.

Authors:  Rhonda Bentley-Lewis; Ellen Seely; Andrea Dunaif
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 5.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

6.  Comparison of clinical features and health manifestations in lean vs. obese Indian women with polycystic ovarian syndrome.

Authors:  Abha Majumdar; Tejshree A Singh
Journal:  J Hum Reprod Sci       Date:  2009-01

Review 7.  Mediators of inflammation in polycystic ovary syndrome in relation to adiposity.

Authors:  Thozhukat Sathyapalan; Stephen L Atkin
Journal:  Mediators Inflamm       Date:  2010-04-08       Impact factor: 4.711

8.  C-reactive protein in obese PCOS women and the effect of metformin therapy.

Authors:  Zelija Velija-Asimi
Journal:  Bosn J Basic Med Sci       Date:  2007-02       Impact factor: 3.363

9.  Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome.

Authors:  L Sun; H Lv; W Wei; D Zhang; Y Guan
Journal:  J Endocrinol Invest       Date:  2009-07-28       Impact factor: 4.256

10.  Serum C-reactive protein levels in normal-weight polycystic ovary syndrome.

Authors:  Ji Young Oh; Ji-Ah Lee; Hyejin Lee; Jee-Young Oh; Yeon-Ah Sung; Hyewon Chung
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.